SUPPORTING INFECTIOUS DISEASE RESEARCH

Monoclonal Pan Anti-Influenza A Virus Nucleoprotein (NP) (produced *in vitro*)

Catalog No. NR-59597 Sino Biological Catalog No. 40205-MM18

For research use only. Not for use in humans.

Contributor and Manufacturer:

Sino Biological, Inc., Wayne, Pennsylvania, USA

Product Description:

Antibody Class: IgG2b

Clone: 18

Mouse monoclonal antibody prepared against the nucleoprotein (NP) of influenza A virus was purified from hybridoma supernatant by protein A affinity chromatography. The B cell hybridoma was generated by the fusion of mouse myeloma cells with splenocytes from mice immunized with purified recombinant Influenza A H1N1 (A/California/07/2009) NP protein (Sino Biological Cat # 40205-V08B; GenPept: ACS94534.1; Met1-Ser498).¹

Material Provided:

Each vial of NR-59597 contains approximately 50 μ L of monoclonal antibody in phosphate buffered saline (PBS). The concentration, expressed as mg/mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-59597 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C to -80°C immediately upon arrival. NR-59597 can be stored at 2°C to 8°C for one month without detectable loss of activity. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-59597 widely recognizes NP of Influenza A virus (Figures 1 and 2). Information on cross-reactivity in ELISA and western blot is shown in Table 1. The optimal concentration and dilution of the antibody to be used in a specific application should be determined by the user.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Pan Anti-Influenza A Virus Nucleoprotein (NP) (produced *in vitro*), NR-59597."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in Microbiological and Biomedical Laboratories (BMBL)</u>. 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Lu, J., Personal Communication.


ATCC[®] is a trademark of the American Type Culture Collection.



E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Figure 1: Representative Western Blot of NR-59597



Lane 1: Influenza A H3N2 (A/Darwin/9/2021)/(A/Darwin/6/2021) NP (Sino Biological 40858-V08B) (10 ng) Lane 2: Influenza B (B/Austria/1359417/2021) NP (Sino Biological 40858-V08B) (10 ng) **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH




Figure 2: Representative Western Blot showing the specificity of NR-59597

b|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Table 1: Cross-reactivity of NR-59597 Nucleoprotein (NP) in ELISA and Western blot

| Cross-reactivity | Immunogen | Catalog #. (Sino Biological) |
|-------------------------|---|---------------------------------|
| ELISA | H1N1 (A/Brevig Mission/1/1918) NP | 40204-V08B |
| | H1N1 (A/Brisbane/02/2018) NP | 40776-V08B |
| | H1N1 (A/California/07/2009) NP | 40205-V08B |
| | H1N1 (A/Guangdong-Maonan/SWL1536/2019) NP | 40723-V08B |
| | H1N1 (A/Hawaii/70/2019) NP | 40724-V08B |
| | H1N1 (A/Michigan/45/2015) NP | 40777-V08B |
| | H1N1 (A/Puerto Rico/8/34/Mount Sinai) NP | 11675-V08B |
| | H1N1 (A/Victoria/2570/2019)/(A/Wisconsin/588/2019) NP | 40774-V08B |
| | H2N2 (A/Ann Arbor/6/1960) NP | 40033-V08B |
| | H3N2 (A/Aichi/2/1968) NP | 40207-V08B |
| | H3N2 (A/Cambodia/e0826360/2020) NP | 40778-V08B |
| | H3N2 (A/Hong Kong/1/1968) NP | 40208-V08B |
| | H3N2 (A/Hong Kong/2671/2019) NP | 40753-V08B |
| | H3N2 (A/Hong Kong/45/2019) NP | 40754-V08B |
| | H3N2 (A/Hong Kong/4801/2014) NP | 40781-V08B |
| | H3N2 (A/Kansas/14/2017) NP | 40779-V08B |
| | H3N2 (A/Switzerland/9715293/2013) NP | 40499-V08B |
| | H7N9 (A/Anhui/1-BALF_RG6/2013) NP | 40110-V08B |
| | H7N9 (A/Shanghai/2/2013) NP | 40111-V08B |
| | Influenza B (B/Brisbane/60/2008) NP | 40783-V08B |
| | Influenza B (B/Colorado/06/2017) NP | 40782-V08B |
| | Influenza B (B/Phuket/3073/2013) NP | 40500-V08B |
| Both ELISA and WB | H3N2 (A/Darwin/9/2021)/(A/Darwin/6/2021) NP | 40858-V08B |
| None in ELISA and WB | Influenza B (B/Austria/1359417/2021) NP | 40861-V08B |
| None in ELISA | SARS-CoV-2 Nucleocapsid Protein | 40588-V08B |
| | HCoV-229E Nucleocapsid Protein | 40640-V07E |
| | HCoV-NL63 Nucleocapsid Protein | 40641-V07E |
| | HCoV-OC43 Nucleocapsid Protein | 40643-V07E |
| | Influenza B (B/Florida/4/2006) NP | 40438-V08B |
| | Influenza B (B/Washington/02/2019) NP | 40755-V08B |